Screening for BCRL in Targeted Therapy for Breast Cancer

Recruiting in Palo Alto (17 mi)

Overseen byAlphonse G. Taghian, MD

Age: 18+

Sex: Female

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Recruiting

Sponsor: Massachusetts General Hospital

No Placebo Group

Trial Summary

What is the purpose of this trial?

This a prospective, longitudinal study designed to track edema and Breast Cancer Related Lymphedema (BCRL) onset in breast cancer patients taking targeted therapy treatments for early and metastatic breast cancer. A Perometer and Sozo devise will be used to measure volume changes

Research Team

Alphonse G. Taghian, MD

Principal Investigator

Massachusetts General Hospital

Eligibility Criteria

Inclusion Criteria

Subjects who are receiving treatment in the MGH Breast Cancer Center who are enrolled in a DF/HCC-regulated targeted therapy trial for the treatment of early or metastatic breast cancer or patients being treated with a targeted therapy that may alter their risk of developing edema or BCRL will be eligible.

Females between 18 and 80 years of age

With a history of breast cancer

See 3 more

Treatment Details

Interventions

Perometer (Device)
SOZO device (Device)

Participant Groups

2Treatment groups

Experimental Treatment

Group I: Target Therapy-Early or Metastatic Breast CancerExperimental Treatment2 Interventions

Screening procedures confirm participation in the research study. * Participants limb volume is measured prior to treatment start date. * Participant is provided informational brochure about risk of lymphedema and Lymphedema Screening Program Card. * Perometer and SOZO measurements will be incorporated as a part of the follow-up visits throughout the course of their trial and for at least 6 months beyond their last dose of trial medication

Group II: Target Therapy Drug-Stand CareExperimental Treatment2 Interventions